Method for prediction of developing metastases in patietns suffering rectal cancer |
|
IPC classes for russian patent Method for prediction of developing metastases in patietns suffering rectal cancer (RU 2420742):
 Diagnostic technique for function-type oddi's sphincter dyssynergia following cholecystectomy / 2416802
Cholecystokinin level is counted additionally in the patients with post-cholecystectomy syndrome. In case the concentration is below 0.5 ng/ml, and while observing no organic pathology of hepatopancreatoduodenal organs as demonstrated by instrument methods, function-type Oddi's sphincter dyssynergia is diagnosed.
Method of predicting duration of recurrence-free period in radically treated patients with mammary gland cancer / 2413231
Content of sex hormones -estradiol and progesterone - in blood is determined. After that coefficient of ratio of estradiol concentration to progesterone concentration is calculated. If values of coefficient are within the range from 10 to 221, duration of recurrence-free period from 5 to 13 years is predicted, and if values of coefficient are within the range 367-1295 recurrence-free period for 28-30 months is predicted.
Method of predicting of process activation in patients with hodgkin's lymphoma / 2405454
Invention relates to medicine, namely to biochemical investigations in oncology, and can be used in determination of activation or stabilisation of pathologic process in patients with primary-resistant Hodgkin's lymphoma. In patients with primary-resistant Hodgkin's lymphoma at stages of treatment, by radioimmune method determined is content in blood of thyroid gland hormones - triiodothyronine and thyroxine, and adrenocortical hormone - cortisol, their concentration is summed up and in case of total level of hormones is within 278.2 nmole/l - 0 333.0 nmole/l conclusion about activation of malignant process is made, if total level of said hormones is 432.4 nmole/l - 833.2 nmole/l conclusion about absence of process activation is made.
Diagnostic technique for severity level of varicocele and its recuring / 2403871
Invention refers to medicine, namely to urology and vascular surgery. The sex hormones level in an involved vein is considered to be a criterion of the severity level of varicocele. There are evaluated the following sex hormones: testosterone, estradiol, progesterone simultaneously in the pampiniform plexus veins of a left ovary and in the peripheral vein of a bend of elbow, with determining the ratio of the sex hormones level in a healthy vein of the bend of elbow to the varicocele-involved pampiniform plexus vein. If said ratio of the sex hormones level is 1:10 to 1:50, the first degree of varicocele is diagnosed. Recurrent varicocele and the second degree of varicocele is diagnosed by the ratio of the sex hormones level in the healthy and involved veins 1:50 to 1:100 times (i.e. hormones concentration in a varicose vein is increased in tens times). If observing the ratio of the sex hormones level in the healthy vein and the involved vein of the pampiniform plexus veins of the left ovary increasing more than in 1:100, the third degree of varicocele is diagnosed. Surgical intervention is indicated if the ratio of the sex hormones level is diagnosed more than 1:50.
 Method of bone resorption to remodelling analysis / 2403870
Invention refers to medicine, namely to biochemistry, surgery and dentistry. The bone resorption to remodeling analysis is based on the biochemical blood examination. An the blood coefficient K1 is calculated by formula: K1=[(PTH:A)+(TNF-α:B)+(IL-1β:C)]:3, where PTH is the parathyroid hormone concentration (pg/ml) in the patients, A is the same value in healthy individuals, TNF-α is the level of tumor necrosis factor -α (pg/ml) in the patients, B is the same value in healthy individuals, IL-1β is the interleukin-1β concentration (pg/ml) in the patients, C is the same value in healthy individuals to derive the blood coefficient K2 by formula: K2=[(calcitonin: D) + (osteocalcin: E)]:2, where the calcitonin concentration (ng/ml) in the patients, D is the same value in healthy individuals, the osteocalcin level (ng/ml) in the patients, E is the same value in healthy individuals. Then the bone metabolism control coefficient (BMCC) is calculated by formula BMCC=K1:K2, and the higher BMCC than 1.17, the more intensive resorption prevails over remodelling; and the lower BMCC than 0.83, the more intensive remodelling prevails over resorption.
Method for assessment of kidney function in felines by measurement of ghrelin hormone levels / 2403573
Method for assessment of kidney function in felines includes determination of observed level of ghrelin in tissue or biofluid of feline and establishment of direct dependence of observed level of ghrelin on kidney function by comparison of observed level of ghrelin with reference level of ghrelin that characterises normal kidney function. Method for diagnostics of kidney disease in felines includes detection of observed level of ghrelin in tissue or biofluid of feline and comparison of observed ghrelin level with referent level of ghrelin, which characterises normal kidney function, where observed level lower than reference level indicates kidney disease or predisposition to it. Method for detection of kidney disease beginning in felines includes monitoring level of ghrelin in tissue or biofluid of feline for a certain period of time; where beginning is identified, if at any moment of time level of ghrelin decreases compared to initial level that characterises healthy kidney function. Diagnostics set includes (a) one or more test materials to detect observed levels of ghrelin in tissue or biofluid of feline; and (b) one or more user-available mediums bearing the following information: (i) reference level of ghrelin that corresponds to a specific feline; and (ii) algorithm of direct dependence of observed ghrelin level relative to reference level on kidney function or reverse dependence of observed ghrelin level relative to reference level on availability of kidney disease or predisposition to kidney disease.
Diagnostic technique for foetal maturity / 2399058
There are determined daily excretion of progesterone metabolite - pregnandiol (Pd), foetal steroids - 16α-hydroxy-ethiocholanolone (16α-OH-Et), 16α-hydroxy-androsterone (16α-OH-An), 16α-hydroxy-dihydroepiandrosterone (16α-OH-DHEA) and oestradiol (Oe) in pregnant women on their 37-42 weeks of pregnancy by capillary gas chromatography. A mature foetus is indicated by the following indices: daily Pd excretion is 150.4-348.3 mcmol/24 hour, 16α-OH-Et - 7.9-16.9 mcmol/24 hour, 16α-OH-An - 6.4-12.6 mkmol/24 hour, 16α-OH-DHEA - 15.4-26.1 mcmol/24 hour, Oe - 24.0-38.7 mcmol/24 hour, while an immature foetus show the indices as follows: daily Pd excretion 80.1-150.2 mcmol/24 hour, 16α-OH-Et - 5.8-7.8 mcmol/24 hour, 16α-OH-An - 4.6-6.3 mcmol/24 hour, 16α-OH-DHEA - 10.2-15.3 mcmol/24 hour, and Oe - 14.5-15.6 mcmol/24 hour, and in a overmature foetus, daily Pd excretion, 16α-OH-Et, 16α-OH-An, 16α-OH-DHEA and Oe are considerably lowered and are less than 50.0 mcmol/24 hour, less than 12.0 mcmol/24 hour, less than 5.8 mcmol/24 hour, less than 4.6 mcmol/24 hour, less than 10.2 mcmol/24 hour, respectively.
Method for prediction of clinical course in disseminated skin melanoma patients / 2399057
Method is implemented by blood analysis for total and free triiodothyronine after the termination of integrated treatment to derive the total to free triiodothyronine ratio, and it is within the range 0.26-0.31, steady state is predicted to be kept in the patients; the ratio within the range 0.19-0.22 ensures to predict the disease generalisation. Technical and economic efficiency of the invention consists in the fact that the derived prognosis factor is an informative laboratory covariant of the favourable or unfavourable development of the pathology.
Method for prediction of effectiveness of neoadjuvant automyelochemotherapy in patients with recurrent breast cancer / 2393484
Prior to begin the therapy, the patient's blood is tested for oestradiol concentration. If the concentration is 18.40 to 29.40 nmol/l, tumour size loss after the neoadjuvant automyelochemotherapy by 67-70% is predicted, that is a partial regress of the tumour, while oestradiol concentration 208.50 to 1541.0 nmol/l enables to predict the tumour size loss by 5-45% that is process stabilisation.
Method for determination severity level of trophological insufficiency in patients with chronic obstructive pulmonary disease / 2390026
Body weight index (BWI) is evaluated; if it is lower than 20 kg/m2, additional analysis is needed to determine the serum leptin concentration. If it is within 16.01±0.64 to 10.15±0.91 ng/ml, the absence of trophological insufficiency is diagnosed, while the values within 5.49±0.46 to 2.26 ng/ml enable to diagnose trophological insufficiency of medium severity, while the values 1.90 to 0.72±0.09 ng/ml indicate severe trophological insufficiency.
Method for differential diagnostics of mammary diseases in men / 2244308
The present innovation deals with biochemical trials: before the onset of therapy in men one should detect blood content of thyroid hormone - free thyroxine - and at its level being 10.3-12.9 pmol/l one should diagnose mammary cancer, at the level of free throxine being 18.7-31.0 pmol/l - one should predict gynecomastia. The method enables to detect the direction of pathological process and carry out due correction of therapy tactics in men with either gynecomastia or mammary cancer.
Method for predicting the delay of intrauterine fetal development / 2246733
The method deals with studying blood serum of pregnant woman to detect the content of insulin-like growth factor (IGF) and vascular-endothelial growth factor (VEGF) and calculate the coefficient of their ratio: at its value being equal to 28.5 and lower it is possible to diagnose the delay of fetal development.
Method for differential diagnostic of chronic hepatitis and hepatic cirrhosis / 2254577
Thyroglobulin content is determined in blood serum using enzyme immunoassay. When thyroglobulin level is increased by 2 times and more compared in contrast with normal one chronic hepatitis is diagnosed, and when thyroglobulin level is decreased by 1.5-2.5 times in contrast with normal one hepatic cirrhosis is diagnosed.
Method for evaluating combined schizophrenia treatment based on atypical antipsychotic drugs and rations and electroconvulsive shock therapy / 2256181
Method involves determining dehydroepiandrosterone sulfate concentration in blood serum. Its growth above 30% when compared to the initial one being observed, treatment efficiency is determined as negative.
Method for diagnosing obliterated forms of congenital suprarenal gland cortex hyperplasia / 2261447
Method involves applying high effectiveness liquid chromatography for determining cortisol, cortisone 11-deoxycorticosterone, 11-deoxycortisone concentration in blood and free cortisol and free cortisone excretion with urine. Ratios of F/E and FF/FE are calculated, where F is the cortisol level in blood; E is the cortisone level in blood; FF is the free cortisol excretion with urine and FE is the free cortisone excretion with urine. The cortisol level in blood not exceeding norm and at least two of three signs: F/E ratio reduction by 25% and more, FF/FE ratio reduction by 25% and more, free cortisol excretion with urine being equal to 25% and more, obliterated forms of congenital suprarenal gland cortex hyperplasia is diagnosed. Corticosterone level in blood growing by 50% and higher, 21-hydroxylase defect is considered to be the case. 11-deoxycorticosterone and/or 11-deoxycortisone concentration in blood being et or greater than 50%, 11β-hydroxylase defect is considered to be the case.
 Method for diagnosing atrophic gastritis cases / 2262706
Method involves making pepsinogen 1, gastrin and Helicopter pylori infection marker combinations analysis and making input of the obtained results into data processing means comprising operation system, means for receiving, transmitting and processing data. The mentioned data processing means is usable for comparing the measured concentration value of a substance under study to a threshold value associated to the substance under study and producing information as a response to comparison results and additionally to other entered data. A set and software are used for implementing the method.
Method for predicting relapse of mammary cancer / 2263319
In the course of surveying in menopausal women after complex therapy one should state the development of mammary cancer at decreased ratio of estriol concentration to the sum of estrone and estradiol urinary concentrations from 1.68±0.23 in relapse-free patients up to 0.74±0.12 - in patients living without relapses for less than a year, up to 0.65±0.13 in patients living without relapse from 2 up to 6 years and up to 0.50±0.10 in patients with relapse-free period from 6 to 10 years. The innovation provides pre-clinical detection of mammary cancer relapse.
Method for predicting fetoplacental insufficiency in pregnant women with thyroid diseases / 2263919
Except detecting placental lactogen in blood serum one should study the content of alphafetoprotein. At placental lactogen content being below 75% against the norm and content of alphafetoprotein below 70% against the norm it is possible to conclude upon availability of fetoplacental insufficiency.
Method for predicting cholecystitis and cholelithiasis / 2263920
While diagnosing cholecystitis and cholelithiasis due to ultrasound testing one should additionally study blood plasma and bile to detect there the content of prostaglandins PGE2 and PGF2α. At PGE2/PGF2α ratio in blood plasma being equal to 6 and more, and, also, at decreased level of biliary cholecystokinin-pancreosimin by 38% and more, biliary PGE2 by 59% and more and increased level of biliary prostaglandin PGF2α by 5.9 times and more against the norm one should diagnose chlecystitis and cholelithiasis. The innovation enables to detect the above-mentioned diseases at earlier stage.
Method for predicting powerless labor in pregnant nodular goiter surgically treated on goiter occasion during pregnancy under medical supervision / 2273456
Method involves determining thyroid gland node diameter and thyrotropic hormone by applying ultrasonic examination approach. Histological examination is carried out with conclusion concerning morphologic nature being obtained like nodular colloid proliferating goiter or thyroid gland adenoma. Diagnostic index Σ is calculated from formula Σ=0.49*K1+0.07*K2-0.5*K3+1.76*K4-1.53, where K1 is the thyroid gland node diameter; K2 is the TTH concentration; K3 is the nodular colloid proliferating goiter index equal to 1 or 0; K4 is the thyroid gland adenoma index equal to 1 or 0. Diagnostic index Σ being less than zero, conclusions concerning powerless labor threat is to be drawn.
|
FIELD: medicine. SUBSTANCE: tissue samples of an tumour and perifocal regions are recovered from the preparation removed intraoperatively. They are analysed for the contents of prolactin and testosterone by radioimmunoassay. If the prolactin concentration is 692.0 ng/g of tissue, and the testosterone concentration is 48.0 ng/g of tissue in the tumour, while the testosterone concentration is 42.0 ng/g of tissue in the perifocal region, developing hepatic metastases are expected in 3 months. If the prolactin concentration is 160-390 ng/g of tissue, and the testosterone concentration is 20-40 ng/g of tissue in the tumour, while the testosterone concentration is 24-26 ng/g of tissue in the perifocal region, developing metastases are expected in 29-43 months. EFFECT: application of the method allows predicting developing metastases in patients suffering rectal cancer at a stage of primary surgical treatment that gives the chance to group the high-risk patients with rapid developing metastases for the purpose of well-timed adequate medical actions to be taken. 2 ex, 1 tbl
The invention relates to medicine, namely to Oncology, and can be used during surgery in patients with rectal cancer and conducting biochemical studies to predict metastases in these patients. Colorectal cancer is a cancer characterized, on the one hand, the steady growth worldwide and in Russia annually reported new cases of the disease, and on the other hand, the low performance in the detection of early forms of malignant process, resulting in more than 80% of patients at the primary treatment of diagnosed tumors in advanced stages. This fact, in turn, determines the high frequency of metastasis of colorectal cancer, which dramatically reduces the 5-year survival of patients. In the aspect above one of the important directions of research remains the search criteria of an increased risk of metastasis in cancer patients given location. It should be emphasized the importance of finding and applying such criteria, which are already at the stage of primary surgical treatment could serve as predictors of individual characteristics further development of the malignant process and metastatic activity of tumor. Similar properties it is advisable to search among the universal regulator the various life processes of the cells of the body as normal, and at a pathology, such as, in particular, hormones. A known method for the diagnosis of metastases in the liver (see Patent No. 2027997 from 27.01.95. Bull. No. 3). The authors proposed a method of detecting metastatic lesions of the liver by determining the activity in the blood of the enzyme gamma-glutamyl transferase after incubation, the serum of patients with homogenate of the liver of intact rats. If after incubation the activity of a specified enzyme increases more than 2 times compared to control, diagnose patients with metastases in the liver. The disadvantage of this method is the absence of the proposed indicator predictor functions in relation to individual characteristics of the interaction in the system of the tumor is the body that are important for post orientation of the disease. A known method for predicting metastasis and/or recurrence of kidney cancer (see Patent No. 2064179 from 20.07.96. Bull. No. 20). The authors investigated the content of daily urine free and total forms of metabolites of adrenal hormones - 17-oxyclozanide in patients with the presence of metastases or recurrence of kidney cancer and found that the magnitude of the ratio of the concentration of free 17-ACS to their aggregate level in the urine within the boundaries of from 0.01 to 0.07 involves patients with metastases or recurrences. The disadvantage of this method I have is, first of all, the fact that the observed ratio between free and total fractions 17-ACS indicates existing patient spread of the disease, but cannot perform the function of a predictor of future development of the process in treated about primary kidney cancer patients. In addition, the proposed method is designed to assess the extent of spread of the disease only in patients with kidney cancer and may not be used for other tumor localization. There is a method of assessing the extent of tumor in malignant tumors of the gastrointestinal tract (Kalinin A.V., Skvortsov, S. Ross. journal of Gastroenterol, gepatol, coloproctol. 1996, Vol.6, No.1, p.32), chosen as a prototype. The authors propose to use to determine the prevalence of malignant process in patients with gastric cancer, pancreatic cancer, extrahepatic bile ducts and bowel research in the serum content of several tumor markers: carbohydrate antigen 19-9 (CA 19-9), cancer-embryonic antigen (CEA) and α-fetoprotein (AFP). Studying the blood levels of these tumor markers, the authors found that CA 19-9 and CEA, with a fairly significant percentage of specificity can be used in differential diagnosticlistener and generalized forms of these diseases, and AFP are useful for detection of liver metastases in patients with cancer of the pancreas and extrahepatic bile ducts. A disadvantage of the proposed method is able to estimate only existing at the time of examination of the patient, the prevalence of malignant process, but the use of the proposed parameters is not possible to predict the characteristics and nature of further development of the disease after treatment of the primary site. The aim of the invention is determining the stage of surgical removal of the tumor nature of further development of the malignant process in patients with rectal cancer. This goal is achieved by the fact that from a remote drug allocate samples of tumor tissue and tissue perifocal zone and radioimmunoassay method determines the content of the hormones prolactin and testosterone. If the prolactin level in the tumor, equal 692,0 ng/g tissue, and the level of testosterone in the tumor, is equal to 48.0 ng/g tissue, and in the perifocal area when testosterone levels equal to 42.0 ng/g tissue, predict development after 3 months of metastases in the liver. When the levels of prolactin in the tumor within the boundaries 160-390 ng/g tissue and testosterone levels in the tumor within the boundaries of 20-40 ng/g tissue, and in the perifocal area when the level of testosterone within the boundaries 24-26 ng/g TC is neither predict the development of metastases through 29-43 month. The invention of "a method for predicting the development of metastases in patients with rectal cancer" is new, because it is unknown in Oncology, surgery for rectal cancer and the prediction of metastases on the basis of biochemical studies. The novelty of the invention lies in the fact that during surgery for cancer of the rectum from a remote drug allocate samples of tumor tissue and tissue perifocal zone and radioimmunoassay method determines the content of the hormones prolactin and testosterone. If the prolactin level in the tumor, equal 692,0 ng/g tissue, and the level of testosterone in the tumor, is equal to 48.0 ng/g tissue, and in the perifocal area when testosterone levels equal to 42.0 ng/g tissue, predict development after 3 months of metastases in the liver. When the levels of prolactin in the tumor within the boundaries 160-390 ng/g tissue and testosterone levels in the tumor within the boundaries of 20-40 ng/g tissue, and in the perifocal area when the level of testosterone within the boundaries 24-26 ng/g tissue predict the development of metastases through 29-43 month. The invention of "a method for predicting the development of metastases in patients with rectal cancer" is industrially applicable and can be repeatedly reproduced in health care in hospitals specialized profile for the treatment of cancer patients with this localization slok the quality of the process. A method for predicting the development of metastases in patients with rectal cancer is as follows. The study included 4 patients with primary rectal cancer stage III with median age 64 years. After surgical removal of the nidus of the drug was provided samples of tumor tissue and tissue perifocal zone. Radioimmunoassay method in tissues spent the determination of prolactin (tumor) and testosterone (tumor and perifocal zone). Found that the hormones in tumor tissue and in tissue perifocal zone fluctuated within a considerable range. After discharge from hospital patients were under observation, during which they have at various times after removal of the primary tumor metastases were identified. Retrospective analysis of the hormonal profile of the tumor and the surrounding tissue was associated with the duration resetstatistics patient survival. It is established that at higher levels in the tumor prolactin (692 ng/g tissue) and testosterone (48,0 ng/g tissue) and a higher level of testosterone in the perifocal area (42,0 ng/g tissue) liver metastases developed in a patient 3 months after removal of the primary tumor of the rectum. In contrast, at lower levels in the tumor prolactin (160-390 ng/g TKA and) and testosterone (20-40 ng/g tissue) and a lower level of testosterone in the perifocal area (24-26 ng/g tissue) metastases in patients has evolved over 29-43 month. The results obtained indicate that the hormonal profile of tumor tissue and perifocal zone is one of the factors associated with the characteristics of metastasis of colorectal cancer, and the levels of prolactin and testosterone in the tumor and testosterone in the perifocal area of the nidus are informative laboratory tests for predictor assessment of the nature of the further development of the disease. Clinical application of the proposed tests will allow us to stage surgical intervention to define groups of patients with a high risk of rapid development of metastases for the implementation of their in-depth survey during dynamic monitoring with a view to timely adequate remedial measures.
Examples of clinical application "method of forecasting development of metastases in patients with colorectal cancer" Sick,, 49, case history No. 335/C. He enrolled in the Department of General Oncology 12.01.07, with a diagnosis of colorectal cancer. Upon receipt complained of constipation, frequent urge to have a bowel movement up to 10-12 times a day, pain when urinating. From history revealed that he considered himself sick about 12 months, when first appeared constipation and frequent urge to have a bowel movement. First contacted CRH in December 2006, where the rector is nascopie a tumor of the rectum and the patient sent to RNII. Admission diagnosis: if fibrocolonoscopia 9 cm is determined by the lower pole bumpy, occupying1/2the circumference of the intestine, stenoderma the lumen of the tumor. Histological analysis No. 914854-55 - adenocarcinoma. Ultrasound 135 from 11.01.07,: diffuse changes of a liver. Signs of focal lesions not. 22.01.2007, after preoperative preparation of the patient is taken to surgery. At laparotomy a tumor of the middle and verneinung division of the rectum up to 6.0 cm in diameter with infiltration adrectal fiber to the sacrum for 10 see Metastasis in the liver was not detected. The patient underwent surgery in the amount of abdomino-perineal removing the rectum with the formation of a single salmostoma. Histological analysis No. 916505-512: usernotification adenocarcinoma with necrosis, ulceration and invasion of all layers of the bowel wall and surrounding tissue. Metastases in the regional lymph nodes were not found. The postoperative period was uneventful, with no complications. 13.02.07, the patient is in satisfactory condition discharged home for postoperative radiotherapy and adjuvant chemotherapy, the oncologist at the place of residence. Postoperative diagnosis: colon cancer, stage 3, after abdomino-perineal removing the rectum with the formation of one who barreled salmostoma 22.01.07, T4N0M0, clinical group 2. When determining the content of hormones in tumor tissue and in the perifocal area found that in tumor tissue concentrations of prolactin and testosterone were 692 ng/g tissue and 48.0 ng/g tissue, respectively, and the level of testosterone in the perifocal area reached 42,0 ng/g of tissue. At the control examination ultrasound No. 3068 from 23.04.07, revealed multiple metastatic liver damage nodes to 4.5 cm in diameter. Recommended palliative chemotherapy and symptomatic treatment by an oncologist at the place of residence. Thus, in a patient with high levels of prolactin and testosterone in the tumor and testosterone in the perifocal area duration resetstatistics period was 3 months. Patient S., 76 years of age, medical history, No. 23894/H. was Admitted to the Department of General Oncology 09.01.07, with a diagnosis of colorectal cancer. Upon receipt complained of the admixture of mucus and blood in the stool, frequent urge to have a bowel movement up to 6-8 times a day. From history revealed that he considered himself sick about 6 months, from time to time, he began to notice the admixture of mucus and blood in the stool, frequent urge to have a bowel movement. First contacted CRH in December 2006, where the finger examination of the rectum and rektoromanoskopii a tumor of the rectum and the patient sent to RNII. When receiving the diagnosis of p is doriden: rektoromanoskopii 8 cm from the anal verge is determined by the lower pole circular tumor, stenoderma the lumen of the intestine with infiltration of the surrounding tissue. Histological analysis No. 58541-43 - adenocarcinoma. 16.01.2007, after preoperative preparation of the patient is taken to surgery. At laparotomy a tumor of srednetemperaturnogo division of the rectum of 5.0×07,0 cm with infiltration adrectal fiber to the sacrum. Metastases in the liver were not observed. The patient underwent surgery in the amount of abdomino-perineal removing the rectum with the formation of a single salmostoma. Histological analysis No. 915109-116: usernotification adenocarcinoma with necrosis, ulceration and invasion of all layers of the bowel wall and surrounding tissue. Metastases in the regional lymph nodes were not found. The postoperative period was uneventful, with no complications. 07.02.2007, the patient is in satisfactory condition discharged home for postoperative radiotherapy and adjuvant chemotherapy, the oncologist at the place of residence. Postoperative diagnosis: colon cancer, stage 3, after abdomino-perineal removing the rectum with the formation of a single salmostoma 16.01.07, T4N0M0, clinical group 2. Determination of hormones in tumor and perifocal tissue showed that the concentrations of prolactin and testosterone in the pathological focus was equal respectively 3900 ng/g tissue and 20.0 ng/g tissue in the level of testosterone in the perifocal area 26,0 ng/g of tissue. At follow-up visits in the 2007-09 biennium signs generalization process is not revealed. Thus, patients with a relatively lower content in the tissues of the studied hormones generalization process is not marked 30 months after surgical treatment. Technical and economic efficiency "method of forecasting the development of metastases in patients with rectal cancer" is that at the stage of primary surgical treatment criteria were found increased risk of metastasis in patients with rectal cancer. While the levels of prolactin and testosterone in the tumor and testosterone in the perifocal area of the nidus are informative laboratory tests for predictor assessment of the nature of the further development of the disease. Clinical application of the proposed tests will allow us to stage surgical intervention to define groups of patients with a high risk of rapid development of metastases for the implementation of their in-depth survey during dynamic monitoring with a view to timely adequate remedial measures. A method for predicting the development of metastases in patients with rectal cancer, including surgery, biochemical study, characterized in that the remote during the operation of the drug produce samples of tumors of the eve tissue and tissue perifocal zone and radioimmunoassay method determines the content of the hormones prolactin and testosterone, if the prolactin level in the tumor, equal 692,0 ng/g tissue, and the level of testosterone in the tumor, is equal to 48.0 ng/g tissue, and in the perifocal area when testosterone levels equal to 42.0 ng/g tissue, predict development after 3 months of metastases in the liver at levels of prolactin in the tumor within the boundaries 160-390 ng/g tissue and testosterone levels in the tumor within the boundaries of 20-40 ng/g tissue, and in the perifocal area when the level of testosterone within the boundaries 24-26 ng/g tissue predict the development of metastases through 29-43 months.
|
